Pfizer, Flynn fined £70m in resurrected epilepsy drug pricing probe
Drugmakers Pfizer and Flynn Pharma have been fined £70 million ($84 million) by the UK Competition and Markets Authority (CMA) for overcharging the NHS for […]
Drugmakers Pfizer and Flynn Pharma have been fined £70 million ($84 million) by the UK Competition and Markets Authority (CMA) for overcharging the NHS for […]
Penalties come after an in-depth investigation carried out by the Competition and Markets Authority The drugmakers Pfizer and Flynn Pharma have been fined a total […]
Considerable scientific progress across neurological diseases and disorders was reported at the recent 74th American Academy of Neurology (AAN) Annual Meeting. What may be important […]
A pill linked to physical malformations, autism and developmental delay in children is still being prescribed to pregnant women A anti-epilepsy drug, which causes health […]
Marinus Pharmaceuticals drug Ztalmy is now FDA approved for treating the seizures in patients who have CDKL5 deficiency, an inherited form of epilepsy. The drug […]
People with CDKL5 deficiency disorder (CDD) now have their first FDA-approved treatment, after the US regulator gave the nod to Marinus Pharma’s Ztalmy for the […]
Neuroscience drug developer Biohaven Pharmaceuticals is expanding its pipeline to include epilepsy and spinal muscular atrophy. The drug developer is acquiring Channel Bioscience and licensing […]
A study has suggested people with epilepsy may show patterns of activity and behaviour on social media that could serve as an early warning signal […]
Epilepsy is a small part of UCB’s neurology pipeline, but its proposed Zogenix acquisition would broaden the Belgium-based drugmaker’s ability to address that market. Zogenix’s […]
Ovid Therapeutics is acquiring global rights to AstraZeneca molecules that address a novel target to treat epilepsy. The AstraZeneca deal comes 10 months after Takeda […]
Patients in Wales with a rare disease that causes epilepsy will be the first in the UK to get access to GW Pharma’s cannabis-based medicine […]
NHS patients in England and Wales with drug-resistant epilepsy are in line for access to another treatment option, after NICE recommended routine use of Angelini […]
Vagus nerve stimulation devices still have a long way to go, but the therapeutic potential of the vagus nerve, the advent of AI and machine […]
The algorithm maps interactions between different areas of the brain, which can help guide the placement of electrodes for stimulating devices to treat brain diseases, […]
GW Pharmaceuticals’ Epidyolex has been approved in the EU for a third epilepsy indication, giving a boost for the company ahead of its $7.2 billion […]
Takeda Pharmaceutical gains full rights to a small molecule that has shown promise treating seizures in several rare forms of epilepsy. Meanwhile, Ovid Therapeutics gains […]
Belgian drugmaker UCB has been steadily building its digital health expertise for several years, and that includes nurturing new projects. One of those is now […]
Shots: UCB invested $29.3M in Nile and as majority shareholder, will be the Board of Directors of Nile with future opportunities to acquire insights and […]
The term Epilepsy isn’t new. It’s been present in the air for centuries now, however, only a few are aware that it is one of […]
What You Should Know: – UCB has selected Medisafe to develop branded digital drug companions for antiepileptic medications, marking the company’s official entry into the […]
The data from a Phase II pilot and an extension study of soticlestat, also known as OV935 or TAK-935, showed short- and long-term reductions of […]
Sanofi has been placed under formal investigation in France for possible charges including manslaughter relating to the epilepsy drug Depakine, following the deaths of four […]
Copyright © 2024 | WordPress Theme by MH Themes